Identification of highly conserved regions in L-segment of crimean-Congo hemorrhagic fever virus and immunoinformatic prediction about potential novel vaccine

Advances and Applications in Bioinformatics and Chemistry

Volumn 8, Issue 1, 2015, Pages 1-10

  Oany, Arafat Rahman ^a   Ahmad, Shah Adil Ishtiyaq ^a   Hossain, Mohammad Uzzal ^a   Jyoti, Tahmina Pervin ^b  

^a MAWLANA BHASHANI SCIENCE AND TECHNOLOGY UNIVERSITY   (Bangladesh)

^b KHULNA UNIVERSITY   (Bangladesh)

Author keywords

Epitope; Immunoinformatics; RNA dependent RNA polymerase; Single stranded RNA

Indexed keywords

CRIMEAN-CONGO HEMORRHAGIC FEVER VIRUS; IXODIDA;

EID: 84940025535     PISSN: None     EISSN: 11786949     Source Type: Journal    
DOI: 10.2147/AABC.S75250     Document Type: Article

References (57)

1. Cunha BA. Tickborne Infectious Diseases: Diagnosis and Management. Vol 24. Boca Raton, FL: CRC Press; 2000.
2. Schmaljohn C, Hooper J. Bunyaviridae: the viruses and their replication. Fields Virol. 2001;2(2):20.
3. Lacy MD, Smego R. Viral hemorrhagic fevers. Adv Pediatr Infect Dis. 1995;12:21-53.
4. Centers for Disease Control and Prevention (CDC). Management of patients with suspected viral hemorrhagic fever. MMWR Morb Mortal Wkly Rep. 1988;37:1.
5. Ergönül Ö. Crimean-Congo haemorrhagic fever. Lancet Infect Dis. 2006;6(4):203-214.
6. Ergonul O. Crimean-Congo hemorrhagic fever virus: new outbreaks, new discoveries. Curr Opin Virol. 2012;2(2):215-220.
7. Swanepoel R, Struthers J, Shepherd A, McGillivray G, Nel M, Jupp P. Crimean-Congo hemorrhagic fever in South Africa. Am J Trop Med Hyg. 1983;32(6):1407-1415.
8. Whitehouse CA. Crimean-Congo hemorrhagic fever. Antiviral Res. 2004;64(3):145-160.
9. David-West TS, Cooke AR, David-West AS. Seroepidemiology of Congo virus (related to the virus of Crimean haemorrhagic fever) in Nigeria. Bull World Health Organ. 1974;51(5):543.
10. Gonzalez J-P, LeGuenno B, Guillaud M, Wilson ML. A fatal case of Crimean-Congo haemorrhagic fever in Mauritania: virological and serological evidence suggesting epidemic transmission. Trans R Soc Trop Med Hyg. 1990;84(4):573-576.
11. Wilson ML, LeGuenno B, Guillaud M, Desoutter D, Gonzalez J-P, Camicas J-L. Distribution of Crimean-Congo hemorrhagic fever viral antibody in Senegal: environmental and vectorial correlates. Am J Trop Med Hyg. 1990;43(5):557-566.
12. Estrada-Peña A, Ruiz-Fons F, Acevedo P, Gortazar C, la Fuente J. Factors driving the circulation and possible expansion of Crimean-Congo haemorrhagic fever virus in the western Palearctic. J Appl Microbiol. 2013;114(1):278-286.
13. Hoogstraal H. The epidemiology of tick-borne Crimean-Congo hemorrhagic fever in Asia, Europe, and Africa. J Med Entomol. 1979;15(4):307-417.
14. Kraus AA, Mirazimi A. Molecular biology and pathogenesis of Crimean-Congo hemorrhagic fever virus. Future Virol. 2010;5(4):469-479.
15. Holland J, Domingo E. Origin and evolution of viruses. Virus Genes. 1998;16(1):13-21.
16. Sette A, Newman M, Livingston B, et al. Optimizing vaccine design for cellular processing, MHC binding and TCR recognition. Tissue Antigens. 2002;59(6):443-451.
17. Sette A, Fikes J. Epitope-based vaccines: an update on epitope identification, vaccine design and delivery. Curr Opin Immunol. 2003;15(4): 461-470.
18. Poland GA, Ovsyannikova IG, Jacobson RM. Application of pharmacogenomics to vaccines. Pharmacogenomics. 2009;10(5):837-852.
19. Petrovsky N, Brusic V. Computational immunology: the coming of age. Immunol Cell Biol. 2002;80(3):248-254.
20. Bourdette DN, Edmonds E, Smith C, et al. A highly immunogenic trivalent T cell receptor peptide vaccine for multiple sclerosis. Mult Scler. 2005;11(5):552-561.
21. López JA, Weilenman C, Audran R, et al. A synthetic malaria vaccine elicits a potent CD8+ and CD4+ T lymphocyte immune response in humans. Implications for vaccination strategies. Eur J Immunol. 2001;31(7):1989-1998.
22. Wilson CC, McKinney D, Anders M, et al. Development of a DNA vaccine designed to induce cytotoxic T lymphocyte responses to multiple conserved epitopes in HIV-1. J Immunol. 2003;171(10):5611-5623.
23. Robinson HL, Amara RR. T cell vaccines for microbial infections. Nat Med. 2005;11:S25-S32.
24. Apweiler R, Bairoch A, Wu CH, et al. UniProt: the universal protein knowledgebase. Nucleic Acids Res. 2004;32(suppl 1):D115-D119.
25. Kinsella E, Martin SG, Grolla A, Czub M, Feldmann H, Flick R. Sequence determination of the Crimean-Congo hemorrhagic fever virus L segment. Virology. 2004;321(1):23-28.
26. Sanchez AJ, Vincent MJ, Nichol ST. Characterization of the glycoproteins of Crimean-Congo hemorrhagic fever virus. J Virol. 2002;76(14): 7263-7275.
27. Hall TA. BioEdit: A User-Friendly Biological Sequence Alignment Editor and analysis Program for Windows 95/98/NT. Paper presented at: Nucleic Acids Symposium Series; 1999; London.
28. Thompson JD, Higgins DG, Gibson TJ. CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucleic Acids Res. 1994;22(22):4673-4680.
29. Waterhouse AM, Procter JB, Martin DM, Clamp M, Barton GJ. Jalview version 2-a multiple sequence alignment editor and analysis workbench. Bioinformatics. 2009;25(9):1189-1191.
30. Doytchinova IA, Flower DR. VaxiJen: a server for prediction of protective antigens, tumour antigens and subunit vaccines. BMC Bioinformatics. 2007;8(1):4.
31. Larsen MV, Lundegaard C, Lamberth K, Buus S, Lund O, Nielsen M. Large-scale validation of methods for cytotoxic T-lymphocyte epitope prediction. BMC Bioinformatics. 2007;8(1):424.
32. Bhasin M, Raghava G. Prediction of CTL epitopes using QM, SVM and ANN techniques. Vaccine. 2004;22(23):3195-3204.
33. Buus S, Lauemøller SL, Worning P, et al. Sensitive quantitative predictions of peptide-MHC binding by a 'Query by Committee' artificial neural network approach. Tissue Antigens. 2003;62(5):378-384.
34. Wang P, Sidney J, Kim Y, et al. Peptide binding predictions for HLA DR, DP and DQ molecules. BMC Bioinformatics. 2010;11(1):568.
35. Wang P, Sidney J, Dow C, Mothe B, Sette A, Peters B. A systematic assessment of MHC class II peptide binding predictions and evaluation of a consensus approach. PLoS Comput Biol. 2008;4(4):e1000048.
36. Peters B, Sette A. Generating quantitative models describing the sequence specificity of biological processes with the stabilized matrix method. BMC Bioinformatics. 2005;6(1):132.
37. Nair DT, Singh K, Siddiqui Z, Nayak BP, Rao KV, Salunke DM. Epitope recognition by diverse antibodies suggests conformational convergence in an antibody response. J Immunol. 2002;168(5):2371-2382.
38. Kolaskar A, Tongaonkar PC. A semi-empirical method for prediction of antigenic determinants on protein antigens. FEBS Lett. 1990;276(1): 172-174.
39. Emini EA, Hughes JV, Perlow D, Boger J. Induction of hepatitis A virus-neutralizing antibody by a virus-specific synthetic peptide. J Virol. 1985;55(3):836-839.
40. Larsen JE, Lund O, Nielsen M. Improved method for predicting linear B-cell epitopes. Immunome Res. 2006;2(1):2.
41. Šali A, Potterton L, Yuan F, van Vlijmen H, Karplus M. Evaluation of comparative protein modeling by MODELLER. Proteins. 1995;23(3): 318-326.
42. Laskowski RA, Rullmann JAC, MacArthur MW, Kaptein R, Thornton JM. AQUA and PROCHECK-NMR: programs for checking the quality of protein structures solved by NMR. J Biomol NMR. 1996;8(4): 477-486.
43. Benkert P, Biasini M, Schwede T. Toward the estimation of the absolute quality of individual protein structure models. Bioinformatics. 2011;27(3):343-350.
44. Arnold K, Bordoli L, Kopp J, Schwede T. The SWISS-MODEL workspace: a web-based environment for protein structure homology modelling. Bioinformatics. 2006;22(2):195-201.
45. Ward JJ, McGuffin LJ, Bryson K, Buxton BF, Jones DT. The DISOPRED server for the prediction of protein disorder. Bioinformatics. 2004;20(13):2138-2139.
46. Garcia-Boronat M, Diez-Rivero CM, Reinherz EL, Reche PA. PVS: a web server for protein sequence variability analysis tuned to facilitate conserved epitope discovery. Nucleic Acids Res. 2008;36(Suppl 2): W35-W41.
47. Saha S, Raghava G. AlgPred: prediction of allergenic proteins and mapping of IgE epitopes. Nucleic Acids Res. 2006;34(Suppl 2): W202-W209.
48. Bui H-H, Sidney J, Li W, Fusseder N, Sette A. Development of an epitope conservancy analysis tool to facilitate the design of epitope-based diagnostics and vaccines. BMC Bioinformatics. 2007; 8(1):361.
49. Shrestha B, Diamond MS. Role of CD8+ T cells in control of West Nile virus infection. J Virol. 2004;78(15):8312-8321.
50. Arnon R. A novel approach to vaccine design - epitope-based vaccines. FEBS J. 2006;273:33-34.
51. McKeever TM, Lewis SA, Smith C, Hubbard R. Vaccination and allergic disease: a birth cohort study. Am J Public Health. 2004; 94(6):985.
52. Buttigieg KR, Dowall SD, Findlay-Wilson S, et al. A novel vaccine against Crimean-Congo haemorrhagic fever protects 100% of animals against lethal challenge in a mouse model. PLoS One. 2014;9(3):e91516.
53. Lu R, Yu X, Wang W, et al. Characterization of human coronavirus etiology in Chinese adults with acute upper respiratory tract infection by real-time RT-PCR assays. PLoS One. 2012;7(6):e38638.
54. Lapelosa M, Gallicchio E, Arnold GF, Arnold E, Levy RM. In silico vaccine design based on molecular simulations of rhinovirus chimeras presenting HIV-1 gp41 epitopes. J Mol Biol. 2009;385(2): 675-691.
55. Chakraborty S, Chakravorty R, Ahmed M, et al. A computational approach for identification of epitopes in dengue virus envelope protein: a step towards designing a universal dengue vaccine targeting endemic regions. In Silico Biol. 2010;10(5):235-246.
56. Oany AR, Emran AA, Jyoti TP. Design of an epitope-based peptide vaccine against spike protein of human corona virus: an in silico approach. Drug Des Devel Ther. 2014;8:1139-1149.
57. Khan MK, Zaman S, Chakraborty S, et al. In silico predicted mycobacterial epitope elicits in vitro T-cell responses. Mol Immunol. 2014;61(1):16-22.